MedPactos osteosarcoma drug vactosertib wins EMAs orphan drug designation - KBR
| 235980 Stock | KRW 4,650 50.00 1.06% |
About 61% of MedPacto's investor base is looking to short. The analysis of current outlook of investing in MedPacto suggests that many traders are alarmed regarding MedPacto's prospects. The current market sentiment, together with MedPacto's historical and current headlines, can help investors time the market. In addition, many technical investors use MedPacto stock news signals to limit their universe of possible portfolio assets.
MedPacto |
MedPactos osteosarcoma drug vactosertib wins EMAs orphan drug designation KBR
Read at news.google.com
 |
MedPacto Fundamental Analysis
We analyze MedPacto's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedPacto using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedPacto based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
MedPacto is rated third in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
MedPacto Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MedPacto stock to make a market-neutral strategy. Peer analysis of MedPacto could also be used in its relative valuation, which is a method of valuing MedPacto by comparing valuation metrics with similar companies.
Peers
MedPacto Related Equities
| 302440 | SK Bioscience | 8.65 | ||||
| 207940 | Samsung Biologics | 0.62 | ||||
| 144510 | Green Cross | 0.20 | ||||
| 235980 | MedPacto | 1.06 | ||||
| 334970 | Prestige Biologics | 1.92 | ||||
| 086890 | ISU Abxis | 2.92 | ||||
| 226950 | OliX PharmaceuticalsI | 3.11 |
Complementary Tools for MedPacto Stock analysis
When running MedPacto's price analysis, check to measure MedPacto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedPacto is operating at the current time. Most of MedPacto's value examination focuses on studying past and present price action to predict the probability of MedPacto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedPacto's price. Additionally, you may evaluate how the addition of MedPacto to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |